Xaga Surgical’s core product is a proprietary prostate biopsy device with a redesigned needle architecture that clinical studies indicate can reduce bacterial transmission by up to 96% and provide a more stable trajectory during tissue sampling. The company received FDA 510(k) clearance for the device and it is already being used by clinicians at institutions such as the Penn State College of Medicine. Xaga was founded by urologist Dr. Andreas Forsvall, who developed the technology based on clinical shortcomings he observed. Xaga reports that traditional biopsy needles contribute to complications in roughly 3% of procedures globally, and its device aims to lower those risks while improving diagnostic accuracy. The company recently raised 17 million SEK (≈€1.6M) to scale manufacturing and commercial operations in the U.S., prepare for CE marking in Europe, and pursue a broader portfolio of infection-prevention technologies for needle-based procedures.

Total raised

$3M

Funding rounds

2

Latest round

Equity

Latest activity

Jul 2026